poisar

Stocks · News reference

Tenax Therapeutics Reports Phase 3 LEVEL Trial Of TNX‑103 In PH‑HFpEF; Study Did Not Meet Primary Or Key Secondary Endpoints

BenzingaAug 10, 2026, 11:07 AMBenzinga Newsdesk

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placeboIn prespecified exploratory analyses in the overall trial population, treatment with TNX-103

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 10, 2026, 11:07 AM
Checked
Aug 10, 2026, 11:07 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading